Viveve Medical Management

Management criteria checks 2/4

We currently do not have sufficient information about the CEO.

Key information

Chief executive officer

n/a

Total compensation

CEO salary percentage	n/a
CEO tenure	no data
CEO ownership	n/a
Management average tenure	6.3yrs
Board average tenure	6.8yrs

Recent management updates

Recent updates

Viveve to get US patent for technology to treat female stress urinary incontinence

Oct 04

Viveve jumps 19% after FDA clearance for expansion of manufacturing treatment tips

Dec 03

CEO

Viveve Medical has no CEO, or we have no data on them.

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Jim Robbins	Senior VP of Finance & Administration and Principal Accounting & Financial Officer	6.8yrs	US$701.05k	no data
Deborah Jorn	Senior Advisor to the CEO & Director	6yrs	US$208.88k	no data
Martin Kerber	Vice President of Research	6.3yrs	no data	no data
Jeannie Swindle	Senior Director of Corporate Communications	no data	no data	no data
Jeff Sinclair	Vice President of International Sales	no data	no data	no data
Gary Kaiser	Vice President of Global Marketing	no data	no data	no data
Lori McMillan	Vice President of Human Resources	7yrs	no data	no data
Suzon Lommel	Senior Vice President of Regulatory & Quality Affairs	6.3yrs	no data	no data

6.3yrs

Average Tenure

65yo

Average Age

Experienced Management: VIVE's management team is seasoned and experienced (6.3 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Deborah Jorn	Senior Advisor to the CEO & Director	8yrs	US$208.88k	no data
Arlene Morris	Independent Director	8yrs	US$232.63k	no data
Steven Basta	Independent Chairman of the Board	5.7yrs	US$469.44k	no data
Alan Wein	Member of Clinical Advisory Board in Urinary Incontinence	no data	no data	no data
Sharon Presnell	Independent Director	3.6yrs	US$196.13k	no data
Roger Dmochowski	Member of Clinical Advisory Board in Urinary Incontinence	no data	no data	no data
Mickey Karram	Member of Clinical Advisory Board in Urinary Incontinence	no data	no data	no data
Kathleen Kobashi	Member of Clinical Advisory Board in Urinary Incontinence	no data	no data	no data
Scott MacDiarmid	Member of Clinical Advisory Board in Urinary Incontinence	no data	no data	no data
Eric Rovner	Member of Clinical Advisory Board in Urinary Incontinence	no data	no data	no data

6.8yrs

Average Tenure

61yo

Average Age

Experienced Board: VIVE's board of directors are considered experienced (6.8 years average tenure).

Viveve Medical Management

Management criteria checks 2/4

Key information

Recent management updates

Viveve Medical, Inc. Appoints Sharon Collins Presnell to the Board of Directors and Its Audit Committee, Effective October 28, 2020

Recent updates

InMode Ltd. (NasdaqGS:INMD) acquired Intellectual Property Assets of Viveve Medical Inc.

Viveve Medical, Inc.(OTCPK:VIVE) dropped from NASDAQ Composite Index

Viveve Medical, Inc. Intends to File A Form 15 with the Securities and Exchange Commission

Viveve Medical, Inc. Announces Completion of Pivotal US Pursuit Trial for Female Stress Urinary Incontinence

Viveve Medical Receives Notice from the Listing Qualifications Staff of Nasdaq

Viveve Medical Receives a Non-Compliance Letter from Nasdaq

Price target decreased to US$4.68

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Viveve Medical, Inc. announced that it has received $0.014675 million in funding

Viveve Medical, Inc. Announces Notice of Allowance for Second U.S. Method Patent for Treating Female Stress Urinary Incontinence

Viveve to get US patent for technology to treat female stress urinary incontinence

Viveve Medical, Inc. Launches Rebranding Initiative to Reflect Focus on Treatment of Female Stress Urinary Incontinence in Anticipation of U.S. Pivotal Pursuit Trial Readout

Second quarter 2022 earnings: EPS in line with analyst expectations despite revenue beat

Viveve Medical, Inc. to Report Q2, 2022 Results on Aug 11, 2022

Viveve Medical receives patent for dual-energy technology in Taiwan

Viveve Medical Receives a Letter from Nasdaq Regarding Minimum Bid Price Requirement

First quarter 2022 earnings: EPS in line with analyst expectations despite revenue beat

Price target decreased to US$6.88

Consensus revenue estimates fall by 15%

Price target decreased to US$9.63

Viveve Medical, Inc. Announces Initiation of Pivotal U.S. Pursuit Trial in Stress Urinary Incontinence

Viveve Medical, Inc. has completed a Composite Units Offering in the amount of $23.999988 million.

Viveve under pressure after upsizes capital raise, prices offering at $3.40

Viveve Regains Compliance with Nasdaq Continued Listing Rules

Viveve regains compliance with Nasdaq

Viveve Announces FDA 510K Approval to Expand Manufacturing of Treatment Tips

Viveve jumps 19% after FDA clearance for expansion of manufacturing treatment tips

Viveve Medical, Inc. to Report Q3, 2020 Results on Nov 12, 2020

Viveve Medical, Inc. Appoints Sharon Collins Presnell to the Board of Directors and Its Audit Committee, Effective October 28, 2020

Viveve Medical, Inc. to Report Q2, 2020 Results on Aug 13, 2020

Viveve Medical, Inc. announced that it expects to receive $10 million in funding from Lincoln Park Capital, LLC

CEO

Leadership Team

Average Tenure

Average Age

Board Members

Average Tenure

Average Age